Go Deep
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,051 | -1.1 | 2.29 | 0.55 | 172.85 |
| Oct 2026 | 20,193 | -1.1 | 2.20 | 0.55 | 165.68 |
| Oct 2026 | 20,344 | -1.1 | 2.11 | 0.55 | 158.58 |
| Oct 2026 | 20,304 | -1.0 | 2.13 | 0.55 | 160.07 |
| Oct 2026 | 20,142 | -1.1 | 2.23 | 0.55 | 167.83 |
| Oct 2026 | 19,647 | -1.2 | 2.54 | 0.55 | 191.06 |
| Oct 2026 | 19,617 | -1.2 | 2.56 | 0.55 | 192.00 |
| Oct 2026 | 19,556 | -1.3 | 2.60 | 0.55 | 194.45 |
Acumen Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -32,718,000.0 | -20,737,000.0 | -25,138,000.0 | -26,451,000.0 |
| EPS | -0.5 | -0.3 | — | -0.4 |
Acumen Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -121,335,000.0 | -102,329,000.0 | -52,371,000.0 | -42,856,000.0 | — |
| EPS | -2.0 | -1.7 | -1.1 | -1.1 | — |
Acumen Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 122,833,000.0 | 238,992,000.0 | 310,125,000.0 | 196,587,000.0 | — |
| Total Liabilities | 52,403,000.0 | 57,176,000.0 | 43,152,000.0 | 7,812,000.0 | — |
| Total Equity | 70,430,000.0 | 181,816,000.0 | 266,973,000.0 | 188,775,000.0 | — |
Owes vs Owns
Acumen Pharmaceuticals, Inc. owed $0.51 for every $1 it owned in Jun 2026, up from $0.04 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.51× | 0.43× | 0.24× | 0.14× | 0.04× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Acumen Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.1%Receivables 0.5%Other assets 4.1%
How it's funded — Dec 2025
Short-term debt 7.1%Long-term debt 18.2%Other liabilities 16.8%Shareholders' equity 57.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 116.9 | 171.6 | 243.5 | 177.6 |
| Receivables | 0.6 | 0.3 | 0.2 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.2 | 0.3 | 0.5 | 0.3 |
| Intangible assets | 0.0 | 0.1 | 0.2 | 0.0 |
| Long-term investments | 0.0 | 60.0 | 62.6 | 15.8 |
| Other assets | 5.1 | 6.7 | 3.2 | 2.9 |
| Liabilities & equity | ||||
| Short-term debt | 8.8 | 0.1 | 0.9 | 0.1 |
| Long-term debt | 22.4 | 28.4 | 27.3 | 0.0 |
| Payables | 0.6 | 5.6 | 1.4 | 1.6 |
| Other liabilities | 20.7 | 22.9 | 13.6 | 6.1 |
| Shareholders' equity | 70.4 | 181.8 | 267.0 | 188.8 |
| Net tangible assets | 70.4 | 181.7 | 266.8 | 188.8 |
Acumen Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -115,538,000.0 | -86,215,000.0 | -43,064,000.0 | -35,153,000.0 | — |
| Investing Activities | 133,933,000.0 | 48,027,000.0 | -171,671,000.0 | 39,185,000.0 | — |
| Financing Activities | -34,000.0 | 6,928,000.0 | 151,753,000.0 | 3,907,000.0 | — |